Cargando…

A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer

OBJECTIVES: Lung cancer (LC) is often accompanied by significant methylation abnormalities. This study aimed to develop a decision tree (DT) accompanied the stature homeobox 2 gene (SHOX2) / prostaglandin E receptor 4 (PTGER4) gene DNA methylation with traditional tumor marker in the differential di...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Wenhai, Huang, Hao, Zhang, Shuishen, Wang, Xueping, Ouyang, Juan, Lin, Zhichao, Chen, Peisong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791477/
https://www.ncbi.nlm.nih.gov/pubmed/33167712
http://dx.doi.org/10.1177/1073274820969703
_version_ 1783633613457195008
author Huang, Wenhai
Huang, Hao
Zhang, Shuishen
Wang, Xueping
Ouyang, Juan
Lin, Zhichao
Chen, Peisong
author_facet Huang, Wenhai
Huang, Hao
Zhang, Shuishen
Wang, Xueping
Ouyang, Juan
Lin, Zhichao
Chen, Peisong
author_sort Huang, Wenhai
collection PubMed
description OBJECTIVES: Lung cancer (LC) is often accompanied by significant methylation abnormalities. This study aimed to develop a decision tree (DT) accompanied the stature homeobox 2 gene (SHOX2) / prostaglandin E receptor 4 (PTGER4) gene DNA methylation with traditional tumor marker in the differential diagnosis of benign and malignant lung nodule. METHODS: We performed a study with 104 patients enrolled in the LC group and 36 patients in the benign lung diseases group. All the clinical data of these patients were collected through electronic medical record. Total Methylation (TM) status of both SHOX2 and PTGER4 was defined as methylation levels of SHOX2 plus methylation levels of PTGER4. One-way analysis was used to compare the concentrations of serum samples and t-test was used to compare pairwise mean values between groups. Receiver operating curve (ROC) was used to evaluate the diagnostic value. Furthermore, the strategy was validated in 19 LC patients and 11 patients with benign lung diseases. RESULTS: There were significant differences between the concentration of neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA21 -1) and the methylation levels of SHOX2, PTGER4 and TM in lung benign diseases and cancer group. The AUCs of NSE, CEA, CYFRA21 -1, Methylation SHOX2, Methylation PTGER4 and TM were 0.721 (95% CI: 0.627–0.816), 0.753 (95% CI: 0.673–0.833) and 0.778(95% CI: 0.700–0.856), 0.851(0.786-0.916), 0.847(0.780-0.913) and 0.861(0.800-0.922) respectively. We developed a DT model with TM and CYFRA21 -1 used in this study, and the area under the curve (AUC) of DT was 0.921 and the sensitivity up to 0.856. In the validation cohort, the AUC of SHOX2, PTGER4 and TM was also much higher than traditional serum markers. CONCLUSIONS: Our results indicated that the DT model calculated from the TM and CYFRA21 -1 can accurately classify LC and benign diseases, which showed better diagnostic performance than traditional serum parameter.
format Online
Article
Text
id pubmed-7791477
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-77914772021-04-09 A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer Huang, Wenhai Huang, Hao Zhang, Shuishen Wang, Xueping Ouyang, Juan Lin, Zhichao Chen, Peisong Cancer Control Original Research Paper OBJECTIVES: Lung cancer (LC) is often accompanied by significant methylation abnormalities. This study aimed to develop a decision tree (DT) accompanied the stature homeobox 2 gene (SHOX2) / prostaglandin E receptor 4 (PTGER4) gene DNA methylation with traditional tumor marker in the differential diagnosis of benign and malignant lung nodule. METHODS: We performed a study with 104 patients enrolled in the LC group and 36 patients in the benign lung diseases group. All the clinical data of these patients were collected through electronic medical record. Total Methylation (TM) status of both SHOX2 and PTGER4 was defined as methylation levels of SHOX2 plus methylation levels of PTGER4. One-way analysis was used to compare the concentrations of serum samples and t-test was used to compare pairwise mean values between groups. Receiver operating curve (ROC) was used to evaluate the diagnostic value. Furthermore, the strategy was validated in 19 LC patients and 11 patients with benign lung diseases. RESULTS: There were significant differences between the concentration of neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA21 -1) and the methylation levels of SHOX2, PTGER4 and TM in lung benign diseases and cancer group. The AUCs of NSE, CEA, CYFRA21 -1, Methylation SHOX2, Methylation PTGER4 and TM were 0.721 (95% CI: 0.627–0.816), 0.753 (95% CI: 0.673–0.833) and 0.778(95% CI: 0.700–0.856), 0.851(0.786-0.916), 0.847(0.780-0.913) and 0.861(0.800-0.922) respectively. We developed a DT model with TM and CYFRA21 -1 used in this study, and the area under the curve (AUC) of DT was 0.921 and the sensitivity up to 0.856. In the validation cohort, the AUC of SHOX2, PTGER4 and TM was also much higher than traditional serum markers. CONCLUSIONS: Our results indicated that the DT model calculated from the TM and CYFRA21 -1 can accurately classify LC and benign diseases, which showed better diagnostic performance than traditional serum parameter. SAGE Publications 2020-11-10 /pmc/articles/PMC7791477/ /pubmed/33167712 http://dx.doi.org/10.1177/1073274820969703 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Paper
Huang, Wenhai
Huang, Hao
Zhang, Shuishen
Wang, Xueping
Ouyang, Juan
Lin, Zhichao
Chen, Peisong
A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer
title A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer
title_full A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer
title_fullStr A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer
title_full_unstemmed A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer
title_short A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer
title_sort novel diagnosis method based on methylation analysis of shox2 and serum biomarker for early stage lung cancer
topic Original Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791477/
https://www.ncbi.nlm.nih.gov/pubmed/33167712
http://dx.doi.org/10.1177/1073274820969703
work_keys_str_mv AT huangwenhai anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer
AT huanghao anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer
AT zhangshuishen anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer
AT wangxueping anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer
AT ouyangjuan anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer
AT linzhichao anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer
AT chenpeisong anoveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer
AT huangwenhai noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer
AT huanghao noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer
AT zhangshuishen noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer
AT wangxueping noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer
AT ouyangjuan noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer
AT linzhichao noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer
AT chenpeisong noveldiagnosismethodbasedonmethylationanalysisofshox2andserumbiomarkerforearlystagelungcancer